Multivitamin Use After Prostate Cancer Diagnosis Is Associated with Lower Risk of Recurrence: A Prospective Cohort Study from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE)
In a large multi-institutional cohort of 1396 men, postdiagnostic multivitamin use was strongly associated with lower risk of prostate cancer recurrence after surgery or radiation after adjustment for clinical factors. Multivitamin (MV) use is common among men with prostate cancer (PC). However, dat...
Gespeichert in:
| Veröffentlicht in: | European urology oncology Jg. 8; H. 4; S. 1003 - 1009 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Netherlands
Elsevier B.V
01.08.2025
|
| Schlagworte: | |
| ISSN: | 2588-9311, 2588-9311 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | In a large multi-institutional cohort of 1396 men, postdiagnostic multivitamin use was strongly associated with lower risk of prostate cancer recurrence after surgery or radiation after adjustment for clinical factors.
Multivitamin (MV) use is common among men with prostate cancer (PC). However, data on MV use in relation to the risk of PC recurrence are limited.
We conducted a longitudinal observational cohort study in 1396 men with nonmetastatic PC who underwent radical prostatectomy (RP) or radiation therapy (RT) and enrolled in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) study between 1999 and 2018. The primary outcome was PC recurrence, defined as biochemical recurrence or initiation of secondary treatment. Postdiagnostic MV use was ascertained via a questionnaire after diagnosis and before any recurrence. Multivariable Cox proportional-hazards regression models controlled for sociodemographic factors, clinical factors, and health behaviors and were used to calculate adjusted hazards ratios (HRs) and 95% confidence intervals (CIs).
In the study cohort there were 858 (62%) current MV users, 227 (16%) past MV users, and 311 (22%) never users. We observed 119 PC recurrence events over a median follow-up of 4.7 (interquartile range 1.9–9.2) yrs after survey completion. Current MV use was associated with lower risk of PC recurrence (basic model: HR 0.52, 95% CI 0.35–0.78; adjusted model: HR 0.51, 95% CI 0.33–0.78). In stratified analyses, the inverse association between current MV use and PC recurrence was stronger for men with grade group 2 (Gleason 3 + 4) or greater PC (n = 430; HR 0.27, 95% CI 0.13–0.55; p < 0.001) and was not statistically significant for men with grade group 1 (Gleason 3 + 3) PC (n = 966).
MV use after PC diagnosis was associated with lower risk of PC recurrence, particularly in patients with higher-grade disease. This finding warrants validation and further investigation. |
|---|---|
| AbstractList | Multivitamin (MV) use is common among men with prostate cancer (PC). However, data on MV use in relation to the risk of PC recurrence are limited.
We conducted a longitudinal observational cohort study in 1396 men with nonmetastatic PC who underwent radical prostatectomy (RP) or radiation therapy (RT) and enrolled in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) study between 1999 and 2018. The primary outcome was PC recurrence, defined as biochemical recurrence or initiation of secondary treatment. Postdiagnostic MV use was ascertained via a questionnaire after diagnosis and before any recurrence. Multivariable Cox proportional-hazards regression models controlled for sociodemographic factors, clinical factors, and health behaviors and were used to calculate adjusted hazards ratios (HRs) and 95% confidence intervals (CIs).
In the study cohort there were 858 (62%) current MV users, 227 (16%) past MV users, and 311 (22%) never users. We observed 119 PC recurrence events over a median follow-up of 4.7 (interquartile range 1.9-9.2) yrs after survey completion. Current MV use was associated with lower risk of PC recurrence (basic model: HR 0.52, 95% CI 0.35-0.78; adjusted model: HR 0.51, 95% CI 0.33-0.78). In stratified analyses, the inverse association between current MV use and PC recurrence was stronger for men with grade group 2 (Gleason 3 + 4) or greater PC (n = 430; HR 0.27, 95% CI 0.13-0.55; p < 0.001) and was not statistically significant for men with grade group 1 (Gleason 3 + 3) PC (n = 966).
MV use after PC diagnosis was associated with lower risk of PC recurrence, particularly in patients with higher-grade disease. This finding warrants validation and further investigation. Multivitamin (MV) use is common among men with prostate cancer (PC). However, data on MV use in relation to the risk of PC recurrence are limited.BACKGROUND AND OBJECTIVEMultivitamin (MV) use is common among men with prostate cancer (PC). However, data on MV use in relation to the risk of PC recurrence are limited.We conducted a longitudinal observational cohort study in 1396 men with nonmetastatic PC who underwent radical prostatectomy (RP) or radiation therapy (RT) and enrolled in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) study between 1999 and 2018. The primary outcome was PC recurrence, defined as biochemical recurrence or initiation of secondary treatment. Postdiagnostic MV use was ascertained via a questionnaire after diagnosis and before any recurrence. Multivariable Cox proportional-hazards regression models controlled for sociodemographic factors, clinical factors, and health behaviors and were used to calculate adjusted hazards ratios (HRs) and 95% confidence intervals (CIs).METHODSWe conducted a longitudinal observational cohort study in 1396 men with nonmetastatic PC who underwent radical prostatectomy (RP) or radiation therapy (RT) and enrolled in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) study between 1999 and 2018. The primary outcome was PC recurrence, defined as biochemical recurrence or initiation of secondary treatment. Postdiagnostic MV use was ascertained via a questionnaire after diagnosis and before any recurrence. Multivariable Cox proportional-hazards regression models controlled for sociodemographic factors, clinical factors, and health behaviors and were used to calculate adjusted hazards ratios (HRs) and 95% confidence intervals (CIs).In the study cohort there were 858 (62%) current MV users, 227 (16%) past MV users, and 311 (22%) never users. We observed 119 PC recurrence events over a median follow-up of 4.7 (interquartile range 1.9-9.2) yrs after survey completion. Current MV use was associated with lower risk of PC recurrence (basic model: HR 0.52, 95% CI 0.35-0.78; adjusted model: HR 0.51, 95% CI 0.33-0.78). In stratified analyses, the inverse association between current MV use and PC recurrence was stronger for men with grade group 2 (Gleason 3 + 4) or greater PC (n = 430; HR 0.27, 95% CI 0.13-0.55; p < 0.001) and was not statistically significant for men with grade group 1 (Gleason 3 + 3) PC (n = 966).KEY FINDINGS AND LIMITATIONSIn the study cohort there were 858 (62%) current MV users, 227 (16%) past MV users, and 311 (22%) never users. We observed 119 PC recurrence events over a median follow-up of 4.7 (interquartile range 1.9-9.2) yrs after survey completion. Current MV use was associated with lower risk of PC recurrence (basic model: HR 0.52, 95% CI 0.35-0.78; adjusted model: HR 0.51, 95% CI 0.33-0.78). In stratified analyses, the inverse association between current MV use and PC recurrence was stronger for men with grade group 2 (Gleason 3 + 4) or greater PC (n = 430; HR 0.27, 95% CI 0.13-0.55; p < 0.001) and was not statistically significant for men with grade group 1 (Gleason 3 + 3) PC (n = 966).MV use after PC diagnosis was associated with lower risk of PC recurrence, particularly in patients with higher-grade disease. This finding warrants validation and further investigation.CONCLUSIONS AND CLINICAL IMPLICATIONSMV use after PC diagnosis was associated with lower risk of PC recurrence, particularly in patients with higher-grade disease. This finding warrants validation and further investigation. In a large multi-institutional cohort of 1396 men, postdiagnostic multivitamin use was strongly associated with lower risk of prostate cancer recurrence after surgery or radiation after adjustment for clinical factors. Multivitamin (MV) use is common among men with prostate cancer (PC). However, data on MV use in relation to the risk of PC recurrence are limited. We conducted a longitudinal observational cohort study in 1396 men with nonmetastatic PC who underwent radical prostatectomy (RP) or radiation therapy (RT) and enrolled in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) study between 1999 and 2018. The primary outcome was PC recurrence, defined as biochemical recurrence or initiation of secondary treatment. Postdiagnostic MV use was ascertained via a questionnaire after diagnosis and before any recurrence. Multivariable Cox proportional-hazards regression models controlled for sociodemographic factors, clinical factors, and health behaviors and were used to calculate adjusted hazards ratios (HRs) and 95% confidence intervals (CIs). In the study cohort there were 858 (62%) current MV users, 227 (16%) past MV users, and 311 (22%) never users. We observed 119 PC recurrence events over a median follow-up of 4.7 (interquartile range 1.9–9.2) yrs after survey completion. Current MV use was associated with lower risk of PC recurrence (basic model: HR 0.52, 95% CI 0.35–0.78; adjusted model: HR 0.51, 95% CI 0.33–0.78). In stratified analyses, the inverse association between current MV use and PC recurrence was stronger for men with grade group 2 (Gleason 3 + 4) or greater PC (n = 430; HR 0.27, 95% CI 0.13–0.55; p < 0.001) and was not statistically significant for men with grade group 1 (Gleason 3 + 3) PC (n = 966). MV use after PC diagnosis was associated with lower risk of PC recurrence, particularly in patients with higher-grade disease. This finding warrants validation and further investigation. Take Home MessageIn a large multi-institutional cohort of 1396 men, postdiagnostic multivitamin use was strongly associated with lower risk of prostate cancer recurrence after surgery or radiation after adjustment for clinical factors. |
| Author | Van Blarigan, Erin L. Cowan, Janet E. Wang, Lufan Carroll, Peter R. Cedars, Benjamin E. Shee, Kevin Kenfield, Stacey A. Tolstykh, Irina Pace, William A. Broering, Jeanette M. Chan, June M. Langlais, Crystal S. |
| Author_xml | – sequence: 1 givenname: Kevin surname: Shee fullname: Shee, Kevin organization: Department of Urology, University of California-San Francisco, San Francisco, CA, USA – sequence: 2 givenname: Benjamin E. surname: Cedars fullname: Cedars, Benjamin E. organization: Department of Urology, University of California-San Diego, La Jolla, CA, USA – sequence: 3 givenname: Lufan surname: Wang fullname: Wang, Lufan organization: Department of Urology, University of California-San Francisco, San Francisco, CA, USA – sequence: 4 givenname: Stacey A. surname: Kenfield fullname: Kenfield, Stacey A. organization: Department of Urology, University of California-San Francisco, San Francisco, CA, USA – sequence: 5 givenname: Janet E. surname: Cowan fullname: Cowan, Janet E. organization: Department of Urology, University of California-San Francisco, San Francisco, CA, USA – sequence: 6 givenname: Irina surname: Tolstykh fullname: Tolstykh, Irina organization: Department of Epidemiology & Biostatistics, University of California-San Francisco, San Francisco, CA, USA – sequence: 7 givenname: Crystal S. surname: Langlais fullname: Langlais, Crystal S. organization: Department of Epidemiology & Biostatistics, University of California-San Francisco, San Francisco, CA, USA – sequence: 8 givenname: William A. surname: Pace fullname: Pace, William A. organization: Department of Urology, University of California-San Francisco, San Francisco, CA, USA – sequence: 9 givenname: Jeanette M. surname: Broering fullname: Broering, Jeanette M. organization: Department of Surgery, University of California-San Francisco, San Francisco, CA, USA – sequence: 10 givenname: Peter R. surname: Carroll fullname: Carroll, Peter R. organization: Department of Urology, University of California-San Francisco, San Francisco, CA, USA – sequence: 11 givenname: June M. surname: Chan fullname: Chan, June M. organization: Department of Urology, University of California-San Francisco, San Francisco, CA, USA – sequence: 12 givenname: Erin L. surname: Van Blarigan fullname: Van Blarigan, Erin L. email: erin.vanblarigan@ucsf.edu organization: Department of Urology, University of California-San Francisco, San Francisco, CA, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40335395$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUk1vEzEQtVARLaU_gAvysRyy-GtXCUhIUUihUhBVQs6W1zvbON2sU9ubKr-Qv9VZUiKEBJxmRn7vjefNvCQnrW-BkNecZZzx4t06g85ngok8YypjXD0jZyIfDgcjyfnJb_kpuYhxzRhDLONMvCCnikmZy1F-Rn587Zrkdi6ZjWvpMgId1wkCvQk-JpOATkxrsf7kzG3ro4v0OtJxjN46fK3og0srOvMPCJm7eEd9TedguxAAae_p-KfQFiz2QC2_8iHRReqqPa2D39C0OnZAZl8dGy9SwHDrLF0G3_g-mUMEE-yKTtsKzM4HejkxN4vlfPr2FXlemybCxVM8J8ur6ffJl8Hs2-fryXg2sIqLNMiFrQoArqQsoWRmqIZC1nVhlYFSlLXJDYhCVTmUOeKMqoGLgpuqKMuiMFKek8uD7jb4-w5i0hsXLTSNacF3UUu0WDHO2Qihb56gXbmBSm-D25iw17_MRwA_ACzOHAPURwhnut-xXmvcse53rJnSqIycDwcO4JA7B0FH63qvKxfQZV1590_2xz_YtnGts6a5gz3Ete9Ci-5prqPQTC_6G-pPSOSsn6n_8ujvAv9p_gjz0dk0 |
| Cites_doi | 10.3945/ajcn.2009.28474 10.1097/JU.0000000000002735 10.1038/s41416-024-02651-5 10.1007/s10549-013-2548-4 10.1089/acm.2008.0387 10.1002/pros.23441 10.1001/jama.2016.14403 10.7326/M14-0198 10.1007/s10549-011-1557-4 10.1200/JCO.18.02462 10.1200/JCO.2010.28.0362 10.1093/annonc/mdi110 10.1111/j.1464-410X.2004.04759.x 10.1200/JCO.2007.13.5905 10.1097/01.ju.0000158155.33890.e7 10.1016/j.nut.2016.02.013 10.1093/aje/152.2.149 10.1155/2015/728046 10.1001/jama.2012.14641 10.1016/j.juro.2009.07.093 10.1017/S002966510800712X 10.1016/S0090-4295(96)00226-9 10.1158/0008-5472.CAN-07-5259 10.1001/jamainternmed.2013.2299 10.1016/j.canlet.2008.12.011 10.1210/endo.140.3.6561 10.1002/ijc.26348 10.1093/jnci/djk177 10.1001/jamanetworkopen.2024.9053 10.1080/07315724.2013.875423 10.1200/JCO.2009.26.0133 |
| ContentType | Journal Article |
| Copyright | 2025 European Association of Urology European Association of Urology Copyright © 2025 European Association of Urology. Published by Elsevier B.V. All rights reserved. |
| Copyright_xml | – notice: 2025 European Association of Urology – notice: European Association of Urology – notice: Copyright © 2025 European Association of Urology. Published by Elsevier B.V. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.euo.2025.04.014 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2588-9311 |
| EndPage | 1009 |
| ExternalDocumentID | 40335395 10_1016_j_euo_2025_04_014 S2588931125001105 1_s2_0_S2588931125001105 |
| Genre | Journal Article Observational Study |
| GroupedDBID | .1- .FO 0R~ 53G AAEDW AALRI AAQFI AATTM AAXUO AAYWO ABJNI ACIEU ACLOT ACRLP ACVFH ADCNI AEBSH AEIPS AEUPX AFJKZ AFPUW AFRHN AFTJW AFXIZ AIEXJ AIGII AIIUN AIKHN AITUG AJUYK AKBMS AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU APXCP AXJTR BKOJK BNPGV EBS EFJIC EFKBS EFLBG EJD FDB FYGXN M41 ROL SPCBC SSH T5K Z5R AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c412t-52cd6ee1433beb0a84823ff6c4aeb2bfa5ae264d5eb56eea4fe1261ad6bb66a33 |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001591937200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2588-9311 |
| IngestDate | Thu Oct 02 23:56:52 EDT 2025 Tue Sep 23 02:21:14 EDT 2025 Thu Nov 13 04:19:23 EST 2025 Sun Oct 19 01:50:24 EDT 2025 Sat Oct 11 11:50:26 EDT 2025 Sun Oct 19 01:24:32 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Multivitamins Recurrence Radiation therapy Radical prostatectomy Prostate cancer Nutritional supplements |
| Language | English |
| License | Copyright © 2025 European Association of Urology. Published by Elsevier B.V. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c412t-52cd6ee1433beb0a84823ff6c4aeb2bfa5ae264d5eb56eea4fe1261ad6bb66a33 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 40335395 |
| PQID | 3201401109 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_3201401109 pubmed_primary_40335395 crossref_primary_10_1016_j_euo_2025_04_014 elsevier_sciencedirect_doi_10_1016_j_euo_2025_04_014 elsevier_clinicalkeyesjournals_1_s2_0_S2588931125001105 elsevier_clinicalkey_doi_10_1016_j_euo_2025_04_014 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-08-01 |
| PublicationDateYYYYMMDD | 2025-08-01 |
| PublicationDate_xml | – month: 08 year: 2025 text: 2025-08-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | European urology oncology |
| PublicationTitleAlternate | Eur Urol Oncol |
| PublicationYear | 2025 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Dickinson, Blatman, El-Dash, Franco (b0020) 2014; 33 Ng, Meyerhardt, Chan (b0170) 2010; 28 Downer, Kenfield, Stampfer (b0110) 2019; 37 Uzzo, Brown, Horwitz (b0035) 2004; 93 Cooperberg, Broering, Carroll (b0180) 2010; 28 Kristal, Stanford, Cohen, Wicklund, Patterson (b0045) 1999; 8 Langlais, Chan, Kenfield (b0115) 2021; 32 Kantor, Rehm, Du, White, Giovannucci (b0005) 2016; 316 Cooperberg, Pasta, Elkin (b0095) 2005; 173 Velicer, Ulrich (b0010) 2008; 26 Greene, Albertsen, Babaian (b0100) 2009; 182 Khandrika, Kumar, Koul, Maroni, Koul (b0135) 2009; 282 Stevens, McCullough, Diver (b0050) 2005; 16 Poole, Shu, Caan (b0165) 2013; 139 Zhao, Ly, Peehl, Feldman (b0145) 1999; 140 Liu, Van Blarigan, Zhang (b0155) 2024; 7 Lawson, Wright, Subar (b0055) 2007; 99 Rosenberg, Nettey, Gogana (b0150) 2019; 30 Bailey, Gahche, Miller, Thomas, Dwyer (b0015) 2013; 173 Watkins, Erickson, Thun, Mulinare, Heath (b0060) 2000; 152 Ferrucci, McCorkle, Smith, Stein, Cartmel (b0080) 2009; 15 Moyer, U.S. Preventive Services Task Force (b0025) 2014; 160 Tat, Kenfield, Cowan (b0125) 2018; 78 Gaziano, Sesso, Christen (b0075) 2012; 308 Lubeck, Litwin, Henning (b0090) 1996; 48 Kwan, Greenlee, Lee (b0160) 2011; 130 Richman, Carroll, Chan (b0105) 2012; 131 Zhang, Song, Mucci, Giovannucci (b0065) 2022; 208 Zhang, Stopsack, Wu, Song, Mucci, Giovannucci (b0070) 2024; 130 Vance, Azabdaftari, Pop (b0175) 2015; 2015 Wiseman (b0030) 2008; 67 Biesiadecki, Molon, Balawender, Kobylinska, Galiniak (b0130) 2024; 14 Richman, Stampfer, Paciorek, Broering, Carroll, Chan (b0120) 2010; 91 Molassiotis, Fernadez-Ortega, Pud (b0085) 2005; 16 Biesalski, Tinz (b0040) 2017; 33 Kumar, Koul, Khandrika, Meacham, Koul (b0140) 2008; 68 Vance (10.1016/j.euo.2025.04.014_b0175) 2015; 2015 Moyer (10.1016/j.euo.2025.04.014_b0025) 2014; 160 Richman (10.1016/j.euo.2025.04.014_b0105) 2012; 131 Gaziano (10.1016/j.euo.2025.04.014_b0075) 2012; 308 Cooperberg (10.1016/j.euo.2025.04.014_b0095) 2005; 173 Langlais (10.1016/j.euo.2025.04.014_b0115) 2021; 32 Kumar (10.1016/j.euo.2025.04.014_b0140) 2008; 68 Tat (10.1016/j.euo.2025.04.014_b0125) 2018; 78 Uzzo (10.1016/j.euo.2025.04.014_b0035) 2004; 93 Ng (10.1016/j.euo.2025.04.014_b0170) 2010; 28 Watkins (10.1016/j.euo.2025.04.014_b0060) 2000; 152 Kantor (10.1016/j.euo.2025.04.014_b0005) 2016; 316 Wiseman (10.1016/j.euo.2025.04.014_b0030) 2008; 67 Zhang (10.1016/j.euo.2025.04.014_b0070) 2024; 130 Downer (10.1016/j.euo.2025.04.014_b0110) 2019; 37 Kwan (10.1016/j.euo.2025.04.014_b0160) 2011; 130 Dickinson (10.1016/j.euo.2025.04.014_b0020) 2014; 33 Biesalski (10.1016/j.euo.2025.04.014_b0040) 2017; 33 Rosenberg (10.1016/j.euo.2025.04.014_b0150) 2019; 30 Biesiadecki (10.1016/j.euo.2025.04.014_b0130) 2024; 14 Stevens (10.1016/j.euo.2025.04.014_b0050) 2005; 16 Bailey (10.1016/j.euo.2025.04.014_b0015) 2013; 173 Molassiotis (10.1016/j.euo.2025.04.014_b0085) 2005; 16 Zhang (10.1016/j.euo.2025.04.014_b0065) 2022; 208 Cooperberg (10.1016/j.euo.2025.04.014_b0180) 2010; 28 Lubeck (10.1016/j.euo.2025.04.014_b0090) 1996; 48 Liu (10.1016/j.euo.2025.04.014_b0155) 2024; 7 Lawson (10.1016/j.euo.2025.04.014_b0055) 2007; 99 Velicer (10.1016/j.euo.2025.04.014_b0010) 2008; 26 Greene (10.1016/j.euo.2025.04.014_b0100) 2009; 182 Richman (10.1016/j.euo.2025.04.014_b0120) 2010; 91 Zhao (10.1016/j.euo.2025.04.014_b0145) 1999; 140 Kristal (10.1016/j.euo.2025.04.014_b0045) 1999; 8 Ferrucci (10.1016/j.euo.2025.04.014_b0080) 2009; 15 Poole (10.1016/j.euo.2025.04.014_b0165) 2013; 139 Khandrika (10.1016/j.euo.2025.04.014_b0135) 2009; 282 |
| References_xml | – volume: 7 year: 2024 ident: b0155 article-title: Plant-based diets and disease progression in men with prostate cancer publication-title: JAMA Netw Open. – volume: 33 start-page: 76 year: 2017 end-page: 82 ident: b0040 article-title: Multivitamin/mineral supplements: rationale and safety – a systematic review publication-title: Nutrition – volume: 37 start-page: 1499 year: 2019 end-page: 1511 ident: b0110 article-title: Alcohol intake and risk of lethal prostate cancer in the Health Professionals Follow-Up Study publication-title: J Clin Oncol – volume: 14 year: 2024 ident: b0130 article-title: Shedding light on the shadows: oxidative stress and its pivotal role in prostate cancer progression publication-title: Front Oncol – volume: 282 start-page: 125 year: 2009 end-page: 136 ident: b0135 article-title: Oxidative stress in prostate cancer publication-title: Cancer Lett – volume: 16 start-page: 643 year: 2005 end-page: 650 ident: b0050 article-title: Use of multivitamins and prostate cancer mortality in a large cohort of US men publication-title: Cancer Causes Control – volume: 91 start-page: 712 year: 2010 end-page: 721 ident: b0120 article-title: Intakes of meat, fish, poultry, and eggs and risk of prostate cancer progression publication-title: Am J Clin Nutr – volume: 208 start-page: 633 year: 2022 end-page: 640 ident: b0065 article-title: Regular, long-duration multivitamin use and risk of overall and aggressive prostate cancer in the Health Professionals Follow-Up Study publication-title: J Urol – volume: 182 start-page: 2232 year: 2009 end-page: 2241 ident: b0100 article-title: Prostate specific antigen best practice statement: 2009 update publication-title: J Urol – volume: 28 start-page: 1117 year: 2010 end-page: 1123 ident: b0180 article-title: Time trends and local variation in primary treatment of localized prostate cancer publication-title: J Clin Oncol – volume: 33 start-page: 176 year: 2014 end-page: 182 ident: b0020 article-title: Consumer usage and reasons for using dietary supplements: report of a series of surveys publication-title: J Am Coll Nutr – volume: 131 start-page: 201 year: 2012 end-page: 210 ident: b0105 article-title: Vegetable and fruit intake after diagnosis and risk of prostate cancer progression publication-title: Int J Cancer – volume: 308 start-page: 1871 year: 2012 end-page: 1880 ident: b0075 article-title: Multivitamins in the prevention of cancer in men: the Physicians’ Health Study II randomized controlled trial publication-title: JAMA – volume: 152 start-page: 149 year: 2000 end-page: 162 ident: b0060 article-title: Multivitamin use and mortality in a large prospective study publication-title: Am J Epidemiol – volume: 140 start-page: 1205 year: 1999 end-page: 1212 ident: b0145 article-title: Induction of androgen receptor by 1α,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells publication-title: Endocrinology – volume: 16 start-page: 655 year: 2005 end-page: 663 ident: b0085 article-title: Use of complementary and alternative medicine in cancer patients: a European survey publication-title: Ann Oncol – volume: 48 start-page: 773 year: 1996 end-page: 777 ident: b0090 article-title: The CaPSURE database: a methodology for clinical practice and research in prostate cancer publication-title: Urology – volume: 68 start-page: 1777 year: 2008 end-page: 1785 ident: b0140 article-title: Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype publication-title: Cancer Res – volume: 67 start-page: 253 year: 2008 end-page: 256 ident: b0030 article-title: The Second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective publication-title: Proc Nutr Soc – volume: 26 start-page: 665 year: 2008 end-page: 673 ident: b0010 article-title: Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review publication-title: J Clin Oncol – volume: 173 start-page: 1938 year: 2005 end-page: 1942 ident: b0095 article-title: The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy publication-title: J Urol – volume: 28 start-page: 4354 year: 2010 end-page: 4363 ident: b0170 article-title: Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803 publication-title: J Clin Oncol – volume: 2015 year: 2015 ident: b0175 article-title: Thioredoxin 1 in prostate tissue is associated with Gleason score, erythrocyte antioxidant enzyme activity, and dietary antioxidants publication-title: Prostate Cancer – volume: 15 start-page: 673 year: 2009 end-page: 680 ident: b0080 article-title: Factors related to the use of dietary supplements by cancer survivors publication-title: J Altern Complement Med – volume: 99 start-page: 754 year: 2007 end-page: 764 ident: b0055 article-title: Multivitamin use and risk of prostate cancer in the National Institutes of Health–AARP Diet and Health Study publication-title: J Natl Cancer Inst – volume: 93 start-page: 955 year: 2004 end-page: 960 ident: b0035 article-title: Prevalence and patterns of self‐initiated nutritional supplementation in men at high risk of prostate cancer publication-title: BJU Int – volume: 32 start-page: 635 year: 2021 end-page: 644 ident: b0115 article-title: Post-diagnostic coffee and tea consumption and risk of prostate cancer progression by smoking history publication-title: Cancer Causes Control – volume: 139 start-page: 529 year: 2013 end-page: 537 ident: b0165 article-title: Postdiagnosis supplement use and breast cancer prognosis in the After Breast Cancer Pooling Project publication-title: Breast Cancer Res Treat – volume: 173 start-page: 355 year: 2013 end-page: 361 ident: b0015 article-title: Why US adults use dietary supplements publication-title: JAMA Intern Med – volume: 8 start-page: 887 year: 1999 end-page: 892 ident: b0045 article-title: Vitamin and mineral supplement use is associated with reduced risk of prostate cancer publication-title: Cancer Epidemiol Prev Biomarkers – volume: 30 start-page: 207 year: 2019 end-page: 214 ident: b0150 article-title: Physiologic serum 1,25 dihydroxyvitamin D is inversely associated with prostatic Ki67 staining in a diverse sample of radical prostatectomy patients publication-title: Cancer Causes Control – volume: 160 start-page: 558 year: 2014 end-page: 564 ident: b0025 article-title: Vitamin, mineral, and multivitamin supplements for the primary prevention of cardiovascular disease and cancer: U.S. Preventive Services Task Force recommendation statement publication-title: Ann Intern Med – volume: 130 start-page: 1709 year: 2024 end-page: 1715 ident: b0070 article-title: Multivitamin use after diagnosis and prostate cancer survival among men with nonmetastatic prostate cancer publication-title: Br J Cancer – volume: 316 start-page: 1464 year: 2016 end-page: 1474 ident: b0005 article-title: Trends in dietary supplement use among US adults from 1999–2012 publication-title: JAMA – volume: 78 start-page: 32 year: 2018 end-page: 39 ident: b0125 article-title: Milk and other dairy foods in relation to prostate cancer recurrence: data from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) publication-title: Prostate – volume: 130 start-page: 195 year: 2011 end-page: 205 ident: b0160 article-title: Multivitamin use and breast cancer outcomes in women with early-stage breast cancer: the Life After Cancer Epidemiology study publication-title: Breast Cancer Res Treat – volume: 91 start-page: 712 year: 2010 ident: 10.1016/j.euo.2025.04.014_b0120 article-title: Intakes of meat, fish, poultry, and eggs and risk of prostate cancer progression publication-title: Am J Clin Nutr doi: 10.3945/ajcn.2009.28474 – volume: 208 start-page: 633 year: 2022 ident: 10.1016/j.euo.2025.04.014_b0065 article-title: Regular, long-duration multivitamin use and risk of overall and aggressive prostate cancer in the Health Professionals Follow-Up Study publication-title: J Urol doi: 10.1097/JU.0000000000002735 – volume: 130 start-page: 1709 year: 2024 ident: 10.1016/j.euo.2025.04.014_b0070 article-title: Multivitamin use after diagnosis and prostate cancer survival among men with nonmetastatic prostate cancer publication-title: Br J Cancer doi: 10.1038/s41416-024-02651-5 – volume: 139 start-page: 529 year: 2013 ident: 10.1016/j.euo.2025.04.014_b0165 article-title: Postdiagnosis supplement use and breast cancer prognosis in the After Breast Cancer Pooling Project publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-013-2548-4 – volume: 15 start-page: 673 year: 2009 ident: 10.1016/j.euo.2025.04.014_b0080 article-title: Factors related to the use of dietary supplements by cancer survivors publication-title: J Altern Complement Med doi: 10.1089/acm.2008.0387 – volume: 78 start-page: 32 year: 2018 ident: 10.1016/j.euo.2025.04.014_b0125 article-title: Milk and other dairy foods in relation to prostate cancer recurrence: data from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) publication-title: Prostate doi: 10.1002/pros.23441 – volume: 316 start-page: 1464 year: 2016 ident: 10.1016/j.euo.2025.04.014_b0005 article-title: Trends in dietary supplement use among US adults from 1999–2012 publication-title: JAMA doi: 10.1001/jama.2016.14403 – volume: 8 start-page: 887 year: 1999 ident: 10.1016/j.euo.2025.04.014_b0045 article-title: Vitamin and mineral supplement use is associated with reduced risk of prostate cancer publication-title: Cancer Epidemiol Prev Biomarkers – volume: 160 start-page: 558 year: 2014 ident: 10.1016/j.euo.2025.04.014_b0025 article-title: Vitamin, mineral, and multivitamin supplements for the primary prevention of cardiovascular disease and cancer: U.S. Preventive Services Task Force recommendation statement publication-title: Ann Intern Med doi: 10.7326/M14-0198 – volume: 130 start-page: 195 year: 2011 ident: 10.1016/j.euo.2025.04.014_b0160 article-title: Multivitamin use and breast cancer outcomes in women with early-stage breast cancer: the Life After Cancer Epidemiology study publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-011-1557-4 – volume: 37 start-page: 1499 year: 2019 ident: 10.1016/j.euo.2025.04.014_b0110 article-title: Alcohol intake and risk of lethal prostate cancer in the Health Professionals Follow-Up Study publication-title: J Clin Oncol doi: 10.1200/JCO.18.02462 – volume: 28 start-page: 4354 year: 2010 ident: 10.1016/j.euo.2025.04.014_b0170 article-title: Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803 publication-title: J Clin Oncol doi: 10.1200/JCO.2010.28.0362 – volume: 16 start-page: 655 year: 2005 ident: 10.1016/j.euo.2025.04.014_b0085 article-title: Use of complementary and alternative medicine in cancer patients: a European survey publication-title: Ann Oncol doi: 10.1093/annonc/mdi110 – volume: 93 start-page: 955 year: 2004 ident: 10.1016/j.euo.2025.04.014_b0035 article-title: Prevalence and patterns of self‐initiated nutritional supplementation in men at high risk of prostate cancer publication-title: BJU Int doi: 10.1111/j.1464-410X.2004.04759.x – volume: 26 start-page: 665 year: 2008 ident: 10.1016/j.euo.2025.04.014_b0010 article-title: Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review publication-title: J Clin Oncol doi: 10.1200/JCO.2007.13.5905 – volume: 173 start-page: 1938 year: 2005 ident: 10.1016/j.euo.2025.04.014_b0095 article-title: The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy publication-title: J Urol doi: 10.1097/01.ju.0000158155.33890.e7 – volume: 32 start-page: 635 year: 2021 ident: 10.1016/j.euo.2025.04.014_b0115 article-title: Post-diagnostic coffee and tea consumption and risk of prostate cancer progression by smoking history publication-title: Cancer Causes Control – volume: 33 start-page: 76 year: 2017 ident: 10.1016/j.euo.2025.04.014_b0040 article-title: Multivitamin/mineral supplements: rationale and safety – a systematic review publication-title: Nutrition doi: 10.1016/j.nut.2016.02.013 – volume: 152 start-page: 149 year: 2000 ident: 10.1016/j.euo.2025.04.014_b0060 article-title: Multivitamin use and mortality in a large prospective study publication-title: Am J Epidemiol doi: 10.1093/aje/152.2.149 – volume: 2015 year: 2015 ident: 10.1016/j.euo.2025.04.014_b0175 article-title: Thioredoxin 1 in prostate tissue is associated with Gleason score, erythrocyte antioxidant enzyme activity, and dietary antioxidants publication-title: Prostate Cancer doi: 10.1155/2015/728046 – volume: 308 start-page: 1871 year: 2012 ident: 10.1016/j.euo.2025.04.014_b0075 article-title: Multivitamins in the prevention of cancer in men: the Physicians’ Health Study II randomized controlled trial publication-title: JAMA doi: 10.1001/jama.2012.14641 – volume: 182 start-page: 2232 year: 2009 ident: 10.1016/j.euo.2025.04.014_b0100 article-title: Prostate specific antigen best practice statement: 2009 update publication-title: J Urol doi: 10.1016/j.juro.2009.07.093 – volume: 30 start-page: 207 year: 2019 ident: 10.1016/j.euo.2025.04.014_b0150 article-title: Physiologic serum 1,25 dihydroxyvitamin D is inversely associated with prostatic Ki67 staining in a diverse sample of radical prostatectomy patients publication-title: Cancer Causes Control – volume: 14 year: 2024 ident: 10.1016/j.euo.2025.04.014_b0130 article-title: Shedding light on the shadows: oxidative stress and its pivotal role in prostate cancer progression publication-title: Front Oncol – volume: 67 start-page: 253 year: 2008 ident: 10.1016/j.euo.2025.04.014_b0030 article-title: The Second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective publication-title: Proc Nutr Soc doi: 10.1017/S002966510800712X – volume: 48 start-page: 773 year: 1996 ident: 10.1016/j.euo.2025.04.014_b0090 article-title: The CaPSURE database: a methodology for clinical practice and research in prostate cancer publication-title: Urology doi: 10.1016/S0090-4295(96)00226-9 – volume: 68 start-page: 1777 year: 2008 ident: 10.1016/j.euo.2025.04.014_b0140 article-title: Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-07-5259 – volume: 173 start-page: 355 year: 2013 ident: 10.1016/j.euo.2025.04.014_b0015 article-title: Why US adults use dietary supplements publication-title: JAMA Intern Med doi: 10.1001/jamainternmed.2013.2299 – volume: 16 start-page: 643 year: 2005 ident: 10.1016/j.euo.2025.04.014_b0050 article-title: Use of multivitamins and prostate cancer mortality in a large cohort of US men publication-title: Cancer Causes Control – volume: 282 start-page: 125 year: 2009 ident: 10.1016/j.euo.2025.04.014_b0135 article-title: Oxidative stress in prostate cancer publication-title: Cancer Lett doi: 10.1016/j.canlet.2008.12.011 – volume: 140 start-page: 1205 year: 1999 ident: 10.1016/j.euo.2025.04.014_b0145 article-title: Induction of androgen receptor by 1α,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells publication-title: Endocrinology doi: 10.1210/endo.140.3.6561 – volume: 131 start-page: 201 year: 2012 ident: 10.1016/j.euo.2025.04.014_b0105 article-title: Vegetable and fruit intake after diagnosis and risk of prostate cancer progression publication-title: Int J Cancer doi: 10.1002/ijc.26348 – volume: 99 start-page: 754 year: 2007 ident: 10.1016/j.euo.2025.04.014_b0055 article-title: Multivitamin use and risk of prostate cancer in the National Institutes of Health–AARP Diet and Health Study publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djk177 – volume: 7 year: 2024 ident: 10.1016/j.euo.2025.04.014_b0155 article-title: Plant-based diets and disease progression in men with prostate cancer publication-title: JAMA Netw Open. doi: 10.1001/jamanetworkopen.2024.9053 – volume: 33 start-page: 176 year: 2014 ident: 10.1016/j.euo.2025.04.014_b0020 article-title: Consumer usage and reasons for using dietary supplements: report of a series of surveys publication-title: J Am Coll Nutr doi: 10.1080/07315724.2013.875423 – volume: 28 start-page: 1117 year: 2010 ident: 10.1016/j.euo.2025.04.014_b0180 article-title: Time trends and local variation in primary treatment of localized prostate cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2009.26.0133 |
| SSID | ssj0002020102 |
| Score | 2.2990766 |
| Snippet | In a large multi-institutional cohort of 1396 men, postdiagnostic multivitamin use was strongly associated with lower risk of prostate cancer recurrence after... Take Home MessageIn a large multi-institutional cohort of 1396 men, postdiagnostic multivitamin use was strongly associated with lower risk of prostate cancer... Multivitamin (MV) use is common among men with prostate cancer (PC). However, data on MV use in relation to the risk of PC recurrence are limited. We conducted... Multivitamin (MV) use is common among men with prostate cancer (PC). However, data on MV use in relation to the risk of PC recurrence are limited.BACKGROUND... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 1003 |
| SubjectTerms | Aged Cohort Studies Humans Longitudinal Studies Male Middle Aged Multivitamins Neoplasm Recurrence, Local - epidemiology Neoplasm Recurrence, Local - prevention & control Nutritional supplements Oncology Prospective Studies Prostate cancer Prostatectomy Prostatic Neoplasms - diagnosis Prostatic Neoplasms - pathology Prostatic Neoplasms - therapy Radiation therapy Radical prostatectomy Recurrence Urology Vitamins - administration & dosage Vitamins - therapeutic use |
| Title | Multivitamin Use After Prostate Cancer Diagnosis Is Associated with Lower Risk of Recurrence: A Prospective Cohort Study from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2588931125001105 https://www.clinicalkey.es/playcontent/1-s2.0-S2588931125001105 https://dx.doi.org/10.1016/j.euo.2025.04.014 https://www.ncbi.nlm.nih.gov/pubmed/40335395 https://www.proquest.com/docview/3201401109 |
| Volume | 8 |
| WOSCitedRecordID | wos001591937200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 2588-9311 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002020102 issn: 2588-9311 databaseCode: AIEXJ dateStart: 20200401 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtZ1LbxMxEICttOXABYF4pUBlJISAaFHWu94HtxClIhCVKA_IzdqHV00Em5BNovILufKTGD-TthTKgcsqseJ1kvl2PB7PeBB6lrtxHgQc1iZumjs-GKROHBeRE5A8KMIcDH4Zm_OpF56cRJNJ3K_VfppcmM2XsCyjs7N48V9FDW0gbJE6-w_itjeFBngNQocriB2u1xK8TKndwJL_67RsjMW5I7IMeF-kd4Bh2WgLOS9B18kYu2nV6FZWSCYWvSdqpzUGOux8IHzyMitQ5bGLW-kETdAnp2DAy3DE79tcFT2Gjj-wQ5ujcLPGeKmUro38a3TKnCcbWe4jaif94XjQMV6KixsH66U6OGpeZuc2BYanKqroA0z2lvk2zxNVBu4tL2fyT7HJF5-1s7y3LrYPCUw9tm43mOIZKM3Wrm-EUBuZp1UooQBH7Gl1zi-3XZpAlC9j9pqvRWYoofIcXJXmev6w7pOP7Hjc67FRZzJ6vvjmiDpmYr9fF3XZQwckpDHo2YNWtzN5b_1-cFNxjJ-oeWi-iNlsl2GHFwa-yly6ajkkzaLRbXRLr2dwS3F4B9V4eRf92GUQA4NYMogNCFjxgS2DuFvhLYNYMIglg1gwiOcF3jL4BrfwDoFYEYglgVgQiIE5MwL0FO_swJZAbAjEhkBsCMQvNH8v76HxcWfUfufoiiFO5rtk5VCS5QHnsAbwUp42k8iPiFcUQeYnPCVpkdCEwwogpzyl8LnEL7hLAjfJgzQNgsTz7qP9cl7yhwi7Reb6WU6LKKfQG3QWKYgbcDCAs4KHSR29MoJhC3UwDDMRkzMGUmRCiqzpM5BiHREjOmYynmGOZkDdnzqFv-vEK61sKuayirAmGwqSBEiwnBHmPK0j3_bUhrQykP824FNDFYNJRuwcJiWfryvmEemIcZtxHT1QuNkf7Tc9j3oxPbxG70fo5vYxfYz2V8s1f4JuZJvVtFoeob1wEh3pB-YXmHQC0g |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Multivitamin+Use+After+Prostate+Cancer+Diagnosis+Is+Associated+with+Lower+Risk+of+Recurrence%3A+A+Prospective+Cohort+Study+from+the+Cancer+of+the+Prostate+Strategic+Urologic+Research+Endeavor+%28CaPSURE%29&rft.jtitle=European+urology+oncology&rft.au=Shee%2C+Kevin&rft.au=Cedars%2C+Benjamin+E&rft.au=Wang%2C+Lufan&rft.au=Kenfield%2C+Stacey+A&rft.date=2025-08-01&rft.issn=2588-9311&rft.eissn=2588-9311&rft_id=info:doi/10.1016%2Fj.euo.2025.04.014&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F25889311%2FS2588931125X00055%2Fcov150h.gif |